Zealand informs of new data on iGlarLixi and proprietary preclinical peptide drug candidates to be presented at the 76th Annual American Diabetes Associations Scientific Sessions
- First time presentations at a scientific congress of results from the two pivotal Phase III trials, LixiLan-L and LixiLan-O, with iGlarLixi
- Presentations in two oral sessions on Sunday, 12 June 2016
COPENHAGEN, Denmark, June 8, 2016 (GLOBE NEWSWIRE) -- Zealand informs that new Phase III data will be presented on iGlarLixi, the fixed-ratio titratable combination of insulin glargine 100 Units/mL (Lantus(r)) and lixisenatide, at the upcoming 76th Scientific Sessions of the American Diabetes Association (ADA), taking place 10- 14 June 2016 in New Orleans, the United States. This is the first time results from these pivotal trials are being presented at a scientific congress.
Further at ADA, Zealand will present new data from its proprietary preclinical activities, including on a novel peptide drug candidate from its preclinical pipeline.
Abstracts of the ADA presentations are available at: http://app.core-apps.com/tristar_ada16
IGlarLixi - Oral presentations of results from two pivotal Phase III trials, LixiLan-O and LixiLan-L
Presentation of results from LixiLan-O (# 186-OR):
"Clinical Impact of Titratable Fixed-Ratio Combination of Insulin Glargine/Lixisenatide vs. Each Component Alone in Type 2 Diabetes Inadequately Controlled on Oral Agents: LixiLan-O Trial"
When: Sunday, 12 June 2016 at 8.45 am CDT
Presenter: Julio Rosenstock, MD, Dallas Diabetes and Endocrine Center
Location: La Nouvelle Orleans AB
Link to abstract: http://app.core-apps.com/tristar_ada16/event/2dcea2d3f4cca64c82bb162014ab0feb
Presentation of results from LixiLan-L (# 238-OR):
"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed-Ratio Combination vs. Insulin Glargine in Patients with T2DM: The LixiLan-L Trial"
When: Sunday, 12 June 2016 at 2.30 pm CDT
Presenter: Vanita R. Aroda, MD, Medstar Health Research Institute
Location: La Nouvelle Orleans AB
Link to abstract: http://app.core-apps.com/tristar_ada16/event/9b73fdfd4b7befbd3fa1b130a88c5086
Zealand poster presentations
Zealand scientists will present posters with new data from two of the company's proprietary preclinical peptide drug projects:
"Antidiabetic Effects of Novel, Long-Acting Amylin Analogue ZP4982 in ZDF Rats" (# 283-LB)
When: 12 June 2016 at 12 pm CDT
Presenter: Jolanta Skarbaliene, Zealand, Denmark
Location: Poster Hall (D-E)
Link to abstract: http://app.core-apps.com/tristar_ada16/abstract/e44e3c20f4b9cf62bd1796c12c19074b
" Model of the Glucose-Insulin-Glucagon Dynamics after Subcutaneous Administration of a Glucagon Rescue Bolus in Healthy Humans" (# 1759-P)
When: 12 June 2016 at 12 pm CDT
Presenter: Sabrina L. Wendt, Zealand, Denmark
Location: Poster Hall (D-E)
Link to abstract: http://app.coreapps.com/tristar_ada16/abstract/92b0eac0f984437a5bebc08c57a7b135
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
